New Chemicals That Block Specific Adenosine Receptors for Treating Diseases
This patent describes new chemical compounds, called fused pyrazine derivatives, designed to block specific adenosine receptors (A2A and A2B) in the body, which could help treat conditions like cancer, inflammatory, cardiovascular, and neurodegenerative diseases.
Original patent title: “Fused pyrazine derivatives as A2A / A2B inhibitors”
This patent describes new chemical compounds, called fused pyrazine derivatives, designed to block specific adenosine receptors (A2A and A2B) in the body, which could help treat conditions like cancer, inflammatory, cardiovascular, and neurodegenerative diseases. Granted in 2026.
Coverage
What does this patent actually cover?
This patent application introduces a group of new chemical compounds, referred to as "compounds of Formula (I)," or their "pharmaceutically acceptable salts." These compounds are designed to change how adenosine receptors, specifically the A2A and A2B subtypes, work in the body. By blocking or reducing the activity of these receptors, the compounds aim to be useful in treating various diseases. For example, they could potentially be used to treat certain types of cancer, reduce inflammation, manage cardiovascular problems, or address neurodegenerative conditions.
The gap
What does this patent NOT cover?
- Does not cover chemical compounds that are not 'fused pyrazine derivatives' or do not fit the specific 'Formula (I)' structure.
- Does not cover compounds that activate A2A or A2B receptors, as the focus is on 'inhibitors' or 'modulators' for treatment.
- Does not cover compounds that exclusively target other adenosine receptor subtypes like A1 or A3, or entirely different types of receptors.
- Does not cover methods of diagnosing diseases using these compounds, only their use in the 'treatment of diseases'.
- Does not cover the treatment of diseases that are not related to the activity of adenosine receptors.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The innovation lies in discovering specific 'fused pyrazine derivatives' with a unique chemical structure (Formula I) that effectively and selectively block A2A and A2B adenosine receptors. This precision in targeting these receptors with a novel compound class offers a new pathway for developing treatments for complex diseases.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Drugs targeting A2A receptors in oncology
Anti-inflammatory medications
Treatments for certain cardiovascular diseases
Therapies for neurodegenerative disorders
Why it matters
The bigger picture
Adenosine receptors, particularly A2A and A2B, play significant roles in many biological processes, including immune responses, inflammation, and heart function. Modulating these receptors is a key strategy in drug development for various serious conditions. This patent aims to provide new chemical tools that could lead to novel drug candidates for major diseases like cancer, where A2A receptor blockade is a known approach to enhance anti-tumor immunity.
Filed
March 28, 2024
Granted
September 15, 2026
Market context
Who's building on this
Companies in this space
Many pharmaceutical and biotechnology companies are actively researching and developing drugs that modulate adenosine receptors, especially for cancer immunotherapy and inflammatory conditions. Companies like AstraZeneca, Bristol Myers Squibb, and various smaller biotechs are exploring similar therapeutic strategies. This patent contributes to the broader effort to find new chemical entities for these targets.
Market impact
If successful, new drugs based on these fused pyrazine derivatives could introduce novel treatment options for patients suffering from cancer, inflammatory, cardiovascular, and neurodegenerative diseases. This could lead to new drug candidates that compete with existing therapies or address unmet medical needs, potentially creating new market segments within these therapeutic areas.
Claim 1 — Plain English
What this patent covers
This patent application introduces a group of new chemical compounds, referred to as "compounds of Formula (I)," or their "pharmaceutically acceptable salts." These compounds are designed to change how adenosine receptors, specifically the A2A and A2B subtypes, work in the body. By blocking or reducing the activity of these receptors, the compounds aim to be useful in treating various diseases. For example, they could potentially be used to treat certain types of cancer, reduce inflammation, manage cardiovascular problems, or address neurodegenerative conditions.
The clever bit
The innovation lies in discovering specific 'fused pyrazine derivatives' with a unique chemical structure (Formula I) that effectively and selectively block A2A and A2B adenosine receptors. This precision in targeting these receptors with a novel compound class offers a new pathway for developing treatments for complex diseases.
What it does not cover
- Does not cover chemical compounds that are not 'fused pyrazine derivatives' or do not fit the specific 'Formula (I)' structure.
- Does not cover compounds that activate A2A or A2B receptors, as the focus is on 'inhibitors' or 'modulators' for treatment.
- Does not cover compounds that exclusively target other adenosine receptor subtypes like A1 or A3, or entirely different types of receptors.
- Does not cover methods of diagnosing diseases using these compounds, only their use in the 'treatment of diseases'.
- Does not cover the treatment of diseases that are not related to the activity of adenosine receptors.
Patent timeline
Application submitted to the patent office
Patent officially issued
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
0/20
Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$36K – $115K
Midpoint $72K · 17.5 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
Concepts involved
Cite this patent
(2026). New Chemicals That Block Specific Adenosine Receptors for Treating Diseases (U.S. Patent No. 12,735,424). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12735424/fused-pyrazine-derivatives-as-a2a-a2b-inhibitors
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12735424"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does New Chemicals That Block Specific Adenosine Receptors for Treating Diseases cover?
This patent describes new chemical compounds, called fused pyrazine derivatives, designed to block specific adenosine receptors (A2A and A2B) in the body, which could help treat conditions like cancer, inflammatory, cardiovascular, and neurodegenerative diseases.
When does this patent expire?
This patent is expected to expire on September 15, 2046, when the invention enters the public domain.
What problem does this patent solve?
Adenosine receptors, particularly A2A and A2B, play significant roles in many biological processes, including immune responses, inflammation, and heart function. Modulating these receptors is a key strategy in drug development for various serious conditions. This patent aims to provide new chemical tools that could lead to novel drug candidates for major diseases like cancer, where A2A receptor blockade is a known approach to enhance anti-tumor immunity.
What does this patent NOT cover?
Does not cover chemical compounds that are not 'fused pyrazine derivatives' or do not fit the specific 'Formula (I)' structure.
Patent monitoring